Literature DB >> 1344973

Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer.

B Fisher1, D L Wickerham, C Redmond.   

Abstract

Entities:  

Mesh:

Year:  1992        PMID: 1344973

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  6 in total

1.  Comparison of Modified Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiation Therapy in Early Breast Cancer in Japaness Women.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

2.  Multidisciplinary approach to the treatment of unresectable breast cancer.

Authors:  Z Z Shen; Y W Zhang; T X Pan; C J Xia
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

3.  Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis.

Authors:  B Thürlimann
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

4.  Adjuvant therapy of breast cancer.

Authors:  N E Davidson; M D Abeloff
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

5.  Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.

Authors:  P Fumoleau; Y Devaux; M L Vo Van; P Kerbrat; P Fargeot; S Schraub; J Mihura; M Namer; M Mercier
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.

Authors:  E van der Wall; W J Nooijen; J W Baars; M J Holtkamp; J H Schorangel; D J Richel; E J Rutgers; I C Slaper-Cortenbach; C E van der Schoot; S Rodenhuis
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.